The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

Your healthcare provider will start you on a lower weekly dose and gradually increase it over time. If you’ve been hearing a lot about GLP-1 receptor agonists like semaglutide, you’re not alone.

but they do not fall into the GLP-1 agonist class. These medicines include orlistat, phentermine and topiramate, and naltrexone/bupropion). A typical Victoza maintenance dose of 1.8mg daily is ...

Eight canines were randomized into two groups who received 0.5mg of semaglutide delivered via oral administration of the RaniPill ® HC (N=4) or subcutaneous injection (N=4). Endpoints included plasma ...